Nanophase Technologies CORP

Solsence, Inc. subsidiary Solsence LLC has entered into a settlement agreement with Refy Beauty Ltd, resolving disputes over consumer care products and initiating a six-month exclusivity period for a new SPF product.

Solsence, Inc. announced its first quarter 2026 financial results, highlighting progress on its 'Transform and Transcend' strategic initiative and a focus on operational excellence.

Solsence, Inc. announced the appointment of Marc James as an independent director to its Board, effective April 24, 2026, enhancing board expertise and corporate governance.

Solsence, Inc. announced record full-year 2025 revenue of $62.1 million, alongside strategic initiatives aimed at sustainable, profitable growth.

Solesence, Inc. has finalized a separation agreement with former CEO Jess Jankowski, detailing severance pay, accelerated stock option vesting, and COBRA premium reimbursements.

Solesence, Inc. announced the retirement of former CEO Jess Jankowski from its Board and his transition to a consulting role, while appointing CEO Kevin Cureton as a new Class III Director.

Solsence, Inc. reported a decrease in total revenue for the first quarter of 2026 compared to the prior year, driven by lower sales in consumer products and advanced materials.

Solsence, Inc. reported a net loss in Q3 2025 despite nine-month revenue growth, as the company continues its strategic pivot towards consumer products.

Solsence, Inc. reported significant revenue and net income growth for Q2 2025, driven by strong performance in consumer products and a strategic shift to skin health.

Solesence Inc. reports a significant increase in revenue for Q1 2025, primarily driven by strong performance in its consumer products segment.

Nanophase Technologies Corporation saw a significant increase in revenue for the third quarter of 2024, primarily driven by its Solsence subsidiary and personal care ingredients segment.

Nanophase Technologies saw a significant increase in revenue during the second quarter of 2024, driven primarily by the growth of its Solsence beauty science subsidiary.

Solsence, Inc. has filed an amendment to its Form 10-K for the fiscal year ended December 31, 2025, primarily to include an inadvertently omitted exhibit.

Solsence, Inc. announced its rebranding and strategic pivot to consumer products, reporting increased revenue but a significant drop in net income and negative cash flow from operations in 2025.

Solesence Inc. (formerly Nanophase Technologies Corporation) reports a significant increase in revenue for 2024, primarily driven by its consumer products segment, and announces a rebranding initiative.

Nanophase Technologies Corporation's 2023 annual report reveals a slight decrease in total revenue but significant growth in its Solsence beauty science business.

SOLESENCE, INC. Director R. Janet Whitmore purchased 2,500 shares of common stock and updated her beneficial ownership, including deferred stock and options.

Solesence Director R. Janet Whitmore increased her direct beneficial ownership of common stock through multiple open market purchases in November 2025.

SOLESENCE, INC. Chief Operating Officer Kevin Cureton executed a series of transactions, exercising stock options and immediately selling 43,500 shares of common stock for proceeds totaling approximately $168,000.

Bradford T. Whitmore, a Director and 10% owner of Solesence, Inc., reported an internal transfer of 6,689,000 common shares between two of his indirectly controlled entities at $4.2 per share, resulting in no net change to his total beneficial ownership.

Director Janet Whitmore reports changes in beneficial ownership of Nanophase Technologies Corp shares, including the acquisition of stock options.

Nanophase Technologies CEO Jess Jankowski reports the acquisition of 22,500 stock options and indirect ownership of 1,000 shares through a spouse's IRA.

Solsence, Inc. has filed its definitive proxy statement for the 2025 Annual Meeting of Stockholders, outlining proposals for director elections, approval of a new equity compensation plan, and ratification of its independent auditors.

Nanophase Technologies Corporation will hold its 2024 Annual Meeting of Stockholders on December 18, 2024, to elect directors and ratify the appointment of auditors.

Nanophase Technologies is asking stockholders to approve an amendment to its Certificate of Incorporation to increase the number of authorized common stock shares from 60,000,000 to 95,000,000, primarily to facilitate the conversion of preferred stock issued to Strandler, LLC.

An amendment to a Schedule 13D filing reveals an internal transfer of 6.689 million shares of Solesence, Inc. common stock between entities controlled by Bradford T. Whitmore, who collectively maintain a 71% beneficial ownership.